renewing system and is considered to be governed by a slowly cycling stem cell (7) . The bulge activation hypothesis has been proposed, which states that the follicular stem cell resides in the bulge area of the permanent portion of the hair follicle and that this stem cell is stimulated during early anagen to divide and produce transient amplifying stem cells (7) . A small group of highly specialized mesenchymal cells, known as the dermal papilla, resides at the base of the epithelial portion of the follicle, and these cells are thought to provide the signal that initiates anagen and instructs the bulge follicular stem cell to divide (19, 27, 30) . The transient amplifying stem cells or matrix cells proliferate and then differentiate under the influence of unidentified morphogens into the inner root sheath cells and the cells that terminally differentiate into the mature hair fiber (13) . At some point, the follicle enters catagen, and after degeneration of the lower follicle, the follicle enters telogen and remains in telogen until the dermal papilla signals the bulge stem cells to divide, and the hair follicle cycle begins again. The actual dermal papilla signals that initiate and terminate the cycles of the hair follicle remain poorly understood.
Using an immunohistochemical approach, our laboratory found that an estrogen receptor (ER) immunoreactive protein is expressed in the nuclei of the dermal papilla cells and that topical treatment of mouse skin with E 2 arrests follicles in telogen, whereas topical treatment with the ER antagonist ICI-182780 causes the telogen follicle to enter anagen and initiate hair growth (29) . These results indicate that an ER pathway within the dermal papilla regulates the telogen-anagen transition of the hair follicle. However, two ERs have now been identified. Recently a novel ER cDNA was cloned from rat prostate, and this ER cDNA was named ER-␤ (23) , to distinguish it from the highly homologous ER cDNA previously cloned in mouse, rat, human, and chicken (now referred to as ER-␣). Rat ER-␤ encodes a 54-kDa protein that is highly homologous to the 65-kDa ER-␣ protein, with ϳ90% amino acid identity in the DNA binding domain and ϳ55% amino acid identity in the COOH-terminal ligand binding domain (23) . Both ER-␣ and ER-␤ are expressed in numerous tissues (8, 32) . In light of this, we wanted to determine whether ER-␣ and/or ER-␤ is expressed in mouse skin.
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Although it appears that the topical application of E 2 and ICI-182780 is directly producing their effects locally within the skin, it is also possible that these compounds are absorbed into the general circulation and are acting in a systemic manner to indirectly alter the hair follicle cycle. In support of such a notion are studies demonstrating that multiple subcutaneous injections of high levels of estradiol benzoate retard hair growth in rats (15) and mice (17) and that gonadectomy and adrenalectomy alter hair growth (17) . In general, it has been difficult to sort out the action of local vs. systemic factors that regulate the hair follicle cycle. This is further complicated by the fact that numerous steroid-synthesizing enzymes, such as aromatase, 17␤-hydroxysteroid dehydrogenase, 3␣-hydroxysteroid dehydrogenase, 3␤-hydroxysteroid dehydrogenase, and 5␣-reductase, are expressed within the hair follicle (33) . In addition, the androgen receptor is also expressed in skin, and androgens are considered to influence the hair follicle cycle (2) . Thus the objectives of this study were to examine 1) the specificity and potency of E 2 compared with other steroid hormones on the follicle cycle, 2) the potency of ICI-182780 compared with other ER antagonists, 3) whether ER-␣ and/or ER-␤ is expressed in mouse skin, and 4) whether the effects of topically applied E 2 and ICI-182780 on the regulation of the hair follicle cycle are due to their local effects within the skin or to a secondary systemic effect resulting from their cutaneous absorption.
MATERIALS AND METHODS
Chemicals. All the chemicals, unless otherwise mentioned, were purchased from Sigma Chemical (St. Louis, MO). ICI-182780 was a kind gift from Zeneca Pharmaceuticals (Wilmington, DE).
Animals. Female CD-1 mice (5 wk old) with identical dates of birth were obtained from Charles River Laboratories (Raleigh, NC) and kept in our animal facility for Ն1 wk before use. They were fed rodent chow and water ad libitum, were kept on corncob bedding, and were placed on a 12:12-h light-dark cycle.
Animal treatment. Dorsal or both dorsal and ventral (depending on the experiment) surfaces were clipped once in the beginning of the study and from then on treated with the respective chemicals in 200 µl acetone or acetone alone twice weekly until full hair regrowth occurred. Full hair regrowth is defined as the complete growth of hair over the entire clipped dorsal surface. For the ovariectomy study, mice were ovariectomized as previously described (26) by use of halothane anesthesia, and they were treated twice a week with either 1 nmol E 2 or acetone from the day of ovariectomy.
Western analysis. Skin from the dorsal surface was removed and homogenized on ice with a polytron homogenizer in 500 µl of buffer [10 mM Tris · HCl (pH 7.5)-1.5 mM EDTA-10 mM ␤-mercaptoethanol] containing (in mM) 0.25 antipain, 0.25 leupeptin, 0.25 aprotinin, and 1 phenylmethylsulfonyl fluoride. Tissue homogenates were centrifuged at 4°C for 50 min in an ultracentrifuge at 105,000 g, and the supernatants were used for the electrophoresis. Protein concentrations of the samples were determined by the method of Lowry et al. (25) . The samples were electrophoresed in an 8% polyacrylamide Novex (San Diego, CA) mini-gel, transferred to a polyvinylidene fluoride membrane, blocked with 5% milk, and then incubated overnight with the primary monoclonal antibody to ER-␣ (either H222 or H226, dilutions 1:2,500; generous gifts from Dr. Geoffrey Greene, University of Chicago). The membranes were washed and incubated with a secondary antibody conjugated to horseradish peroxidase (Amersham, Arlington Heights, IL; dilution 1:5,000) and finally, signals were detected by Amersham enhanced chemiluminescence detection reagent. H222 binds to an ER-␣ epitope within the carboxy F domain; H226 binds to an epitope within NH 2 -terminal transactivation domain of ER-␣.
Ribonuclease protection assay. The ribonuclease protection assay (RPA) for ER-␣ and ER-␤ mRNA was carried out as previously described (8) . Antisense riboprobes were generated from linearized templates by use of the Maxiscript kit (Ambion, Austin, TX) and the incorporation of [ 32 P]CTP (Amersham) according to the manufacturer's protocol. The mouse ER-␣ antisense riboprobe protects a specific fragment of 366 nucleotides (nt), whereas the mouse ER-␤ antisense riboprobe protects a specific fragment of 262 nt. To equate loading among lanes, all reactions included an antisense riboprobe specific for mouse cyclophilin, generated from the template pTRI-Cyclophilin (Ambion) and producing a protected fragment of 103 nt. For all RPA reactions, 5 x 10 4 counts/min (cpm) of each probe, a 10-µg sample RNA, and yeast tRNA (for a final total RNA equal to 25 µg) were mixed and ethanol precipitated at Ϫ70°C for 3 h to overnight. The resulting pellets were then processed through the RPA with the Hybspeed kit (Ambion) according to the manufacturer's protocol. Final analysis of protected fragments was carried out by electrophoresis on a 1.5-mm thick 6% bis-acrylamide-8.3 M urea-1X TBE gel (National Diagnostics, Atlanta, GA), which was then fixed, dried, and exposed to Hyperfilm (Amersham) X-ray film.
RIA. Blood for the RIA was collected by cardiac puncture while the mice were maintained under halothane anesthesia. After the blood was allowed to clot at room temperature, the samples were centrifuged at 1,550 g for 15 min, and the serum was harvested for storage at Ϫ20°C until the assay was performed. A modification of the method previously reported by Cox et al. (9) was used for the RIA. Briefly, after extraction of 25-50 µl of serum once with 4 ml ethyl acetate (carbonyl free grade, Burdick Jackson, Muskegon, MI), the aqueous phase was frozen in a dry ice-methanol bath, and the ethyl acetate was decanted into a test tube for evaporation at 37°C in a dry heat block under a stream of nitrogen. The samples were then reconstituted with 200 µl PBS-gel buffer (0.01 M PBS, 0.1% gelatin, pH 7.0) and incubated overnight at 4°C with 200 µl antibody (diluted 1:1,500,000 with PBSgel). On the next day, 100 µl of tracer diluted with PBS-gel 5ϳ8,000 cpm estradiol-6-(O-carboxymethyl)oximino-(2-[ 125 I]iodohistamine; Amersham)6 were added and incubated at 4°C for 6 h. Dextran-coated charcoal (500 µl containing 0.05% dextran and 0.05% charcoal in PBS-gel) was then added to each sample, vortexed, and incubated for 45 min to adsorb the unbound hormone. Centrifugation at 1,550 g for 15 min was then used to precipitate the charcoal. The supernatant was decanted, and radioactivity was measured using a gamma counter (1272 Clinigamma, Wallac Instruments, Gaithersburg, MD). The amount of estradiol in the samples was determined from a standard curve that was generated using known amounts of estradiol ranging from 0.098 to 12.5 pg per tube. Extraction efficiency (generally Ͼ85%) was monitored by determining the amount of labeled estradiol that was recovered from representative serum samples after ethyl acetate extraction. The values reported have been corrected for these recoveries.
Northern analysis. RNA was extracted by the method of Chomczynski and Sacchi (6) . Briefly, fresh tissue was homogenized in 4 M guanidine thiocyanate-25 mM lithium citrate-0.5% sarcosyl-0.12% ␤-mercaptoethanol-0.1% antifoam A (2 ml/0.1 g tissue). The homogenate was filtered through spectramesh (a macroporous polypropylene filter, 210 µm) into sterile polypropylene tubes to get rid of the hair residuals, and the volume was adjusted back to the original volume with the buffer. After this, 0.1 vol of 2 M sodium acetate (pH 4.0), 1 vol of diethyl pyrocarbonate water-saturated phenol, and 0.2 vol of chloroform:isoamyl alcohol (49:1) were added and vortexed for 15 s. The mixture was allowed to stand on ice for 15 min and then was centrifuged at 10,000 g for 20 min at 4°C (Sorvall RC-5 high-speed centrifuge with rubber adopter). The clear aqueous phase was then carefully taken, an equal volume of cold isopropanol was added, and the mixture was stored at Ϫ20°C for 2 h. Samples were then spun at 11,000 g for 20 min at 4°C. The pellet was then resuspended in homogenization buffer and stored overnight at Ϫ20°C with an equal volume of cold isopropanol to precipitate RNA. Next day the tubes were centrifuged for 20 min at 4°C. The pellets were then washed with 75% and then 95% cold ethanol and dried in a speed-vacuum centrifuge for 10 min. The RNA concentration was determined by ultraviolet absorption at 260 nm. Samples of total RNA and molecular weight markers (GIBCO-BRL, Gaithersberg, MD) were denatured and subjected to size fractionation by a 1% agarose-formaldehyde gel; the RNA was then transferred to a positively charged nylon membrane (Zeta Probe GT; Bio-Rad, Hercules, CA) by use of a Turbo Blotter System (Schleicher and Schuell, Keene, NH). The filter was baked at 80°C for 1 h. After prehybridization at 65°C for 10 min, the membrane was hybridized at 65°C overnight by use of a 32 P-labeled mouse ER-␣ cDNA probe in a hybridization buffer containing 0.25 M sodium phosphate and 7% SDS. The [ 32 P]cDNA probe was prepared by using a random priming kit from GIBCO-BRL with deoxy-[ 32 P]CTP (New England Nuclear, Boston, MA). The specific activities of the cDNA probe were Ͼ10 9 cpm/µg. The filter was washed several times after hybridization with 0.1X standard sodium citrate (1X SSC: 0.15 mol/l sodium chloride and 0.015 mol/l sodium citrate)-0.1% SDS, and then autoradiographed on Kodak XAR-5 film (Eastman Kodak, Rochester, NY) with an intensifying screen at ϳ80°C for 36 h.
RESULTS

Effect of topical application of various steroids and ER antagonists on hair growth.
The hair follicle cycle of mice is highly synchronized from birth to 12 wk of age, with fixed periods of anagen, telogen, and catagen. The second telogen phase in CD-1 mice begins at ϳ6 wk of age and lasts until ϳ9 wk of age, at which time the hair follicles enter the third anagen synchronously. Topically applied E 2 (10 nmol/200 µl acetone, twice a week) to mouse skin has been shown to block hair growth by arresting hair follicles in telogen, whereas 17␣-E 2 was without effect (29) . To further determine the specificity and potency of E 2 , we examined the effect of equimolar doses of a variety of other steroid hormones on hair growth. E 2 , dihydrotestosterone (DHT), androstenedione, testosterone, or progesterone was applied topically twice weekly at a dose of 10 nmol/200 µl acetone vehicle to the clipped dorsal skin of CD-1 female mice beginning at 6 wk and continuing to the 17th wk of age. As shown in Fig. 1 , vehicle control (acetone-treated) mice grew a full coat of hair by 13 wk of age, whereas mice treated with E 2 did not demonstrate any hair growth. Compared with the acetone-treated control mice, testosterone treatment produced a slight inhibitory effect on hair growth, whereas DHT delayed full hair growth by 3-4 wk. Interestingly, androstenedione and progesterone stimulated hair growth. These results demonstrate that, of the steroid hormones examined, E 2 is the most effective at blocking hair growth.
Twice weekly topical application of the ER antagonist ICI-182780 (10 nmol/200 µl acetone) has been shown to stimulate hair growth by causing telogen hair follicles to enter anagen (29) . As shown in Fig. 1B , we compared the effect of equimolar doses of the ER antagonists ICI-182780, nafoxidine, 4-OH tamoxifen, tamoxifen, and clomiphene for their ability to stimulate hair growth. ER antagonists were applied topically twice weekly at a dose of 10 nmol/200 µl acetone vehicle to the clipped dorsal skin of CD-1 female mice beginning at 6 wk and continuing to the 17th wk of age. All of the ER antagonists stimulated hair growth to some extent (Fig. 1B) , but none was as efficacious as ICI-182780. Lower doses of nafoxidine, tamoxifen, and clomiphene were not effective, and increasing the doses of these ER antagonists to 100 nmol/treatment abated the stimulatory effect and actually produced a slight inhibitory effect on hair growth (data not shown). Likewise, increasing the dose of 4-OH tamoxifen to 20 nmol also produced a slight inhibitory effect on hair growth. Tamoxifen has previously been shown to produce both estrogen-antagonist and -agonist responses in mice depending on dose and conditions of administration (20, 28) . Our data are consistent with these earlier findings, in that divergent effects were noted. Appropriately selected low doses of tamoxifen and other antiestrogens that have a similar triphenethylene structure (nafoxidene, clomiphene, and 4-OH tamoxifen) appear to be functioning as antagonists in skin similarly to the pure antagonist ICI-182780. However, higher doses of the triphenethylene antiestrogens appear to exhibit agonist activity in the skin. These results demonstrate that, in addition to ICI-182780, other ER antagonists can stimulate hair growth when administered under proper conditions; however, ICI-182780 is the most effective.
Dose-response relationship of E 2 and ICI-182780 on hair growth, and effect of coadministration of ICI-182780 with E 2 . Dose-response studies were conducted to determine whether lower doses of E 2 and ICI-182780 were capable of modulating hair growth. Different doses (1, 5, and 10 nmol) of E 2 or ICI-182780 were applied topically in 200 µl acetone, twice weekly, to the clipped dorsal surface of 6-wk-old CD-1 female mice. As shown in Fig. 2A , the 1-nmol dose of E 2 was found to be inhibitory to hair growth; however, hair growth inhibition was attenuated with time, and by 18 wk of age, the mice had developed a full coat of hair. In contrast, only 20% of the mice treated with 10 nmol E 2 developed a full coat of hair by 21 wk of age. For the 5-nmol dose, 100% of the mice had a full coat of hair by 20 wk of age. As shown in Fig. 2B , a dose-dependent stimulation of hair growth by ICI-182780 was apparent at the beginning of the treatment period, but the dose dependency was attenuated at later time points. By 10.5 wk of age, all of the mice treated with all three doses of ICI-182780 developed a full coat of hair. To determine whether ICI-182780 could antagonize the inhibitory action of topically applied E 2 , mice were treated topically twice weekly with 1 nmol E 2 along with 10 nmol ICI-182780 (ICI-182780 was applied first, and then E 2 was applied after 1 h). As shown in Fig. 2C, 10 nmol ICI-182780 reversed the inhibitory effect of 1 nmol E 2 on hair growth, further supporting the idea that the effects of E 2 and ICI-182780 on hair growth are mediated through the ER.
ER-␣ but not ER-␤ is expressed in mouse skin. Using an immunohistochemical approach, Oh and Smart (29) demonstrated the presence of an ER immunoreactive protein in the nuclei of the dermal papilla cells of the mouse telogen hair follicle. In the present study, we detected a 6.7-kb ER-␣ mRNA in RNA isolated from 6-wk-old female mouse skin by using a mouse ER-␣ cDNA probe (Fig. 3A) . In addition, Western analysis, using monoclonal antibody H222 to the carboxyterminal F region of ER-␣, or monoclonal antibody H226 to the NH 2 -terminal A/B transactivation region of ER-␣, revealed a 65-kDa ER-␣ immunoreactive protein in mouse skin protein extracts from 6-wk-old mice (Fig.  3B) . A protein of similar size was detected in uterine extracts with these antibodies (data not shown). These results demonstrate that ER-␣ is expressed in mouse skin. Next, we wanted to determine whether ICI-182780, E 2 , or the hair follicle cycle could alter the expression of ER-␣ protein. Six-wk-old female mice were treated topically twice weekly with acetone vehicle, 10 nmol ICI-182780, or 10 nmol E 2 in 200 µl of acetone. At 8 wk of age, mice treated with ICI-182780 had entered anagen (data not shown), and skin protein extracts from these mice demonstrated decreased levels (Ͼ50% as demonstrated by laser densitometry) of ER-␣ H226 immunoreactive protein compared with the vehicle-treated mice, whereas the mice treated with E 2 demonstrated 1.5-fold increased levels of the protein (Fig. 3C) . At 10 wk of age, the hair follicles of the mice treated with acetone were in anagen (data not shown), and skin protein extracts from these mice had levels of the ER-␣ immunoreactive protein similar to those of the ICI-treated group, whereas the protein extracts from E 2 -treated mice demonstrated greater than 3-fold elevated levels of ER-␣, and their follicles remained in telogen. These results indicate that the level of ER-␣ expression is modulated by E 2 and ICI-182780 treatment and by the phase of the hair follicle. To determine whether ER-␤ is expressed in female mouse skin, we conducted an RPA on RNA isolated from mouse skin containing predominantly anagen or telogen hair fol- licles. As shown in Fig. 4 , RPA analysis of mouse skin RNA confirmed the presence of ER-␣ transcripts in RNA isolated from mouse skin containing predominantly telogen or anagen hair follicles; however, ER-␤ transcripts were not detectable in mouse skin. In addition, ER-␤ could not be detected using an ER-␤-specific antibody and Western analysis (data not shown).
Effect of ventral application of 17␤-estradiol and ICI-182780 on dorsal hair growth.
To begin to determine whether the effects of E 2 on hair growth are mediated within the skin itself or due to a systemic effect of cutaneously absorbed topically applied E 2 , we injected 1, 5, or 10 nmol E 2 in corn oil intraperitoneally (ip) into 6-wk-old female mice twice weekly for 7 wk. Intraperitoneal administration of E 2 had no inhibitory effect on hair growth. Previously, we reported that intraperitoneal administration of 10 nmol ICI-182780 at the same dosing frequency was also without effect on hair growth (29) . These results suggest that the effects of E 2 and ICI-182780 are produced locally within the skin; however, it is possible that these compounds are rapidly metabolized and/or eliminated after intraperitoneal administration. Therefore, in a further effort to determine whether E 2 and ICI-182780 are functioning directly within the skin, 6-wk-old mice were treated topically twice weekly with either 1 nmol or 10 nmol E 2 or 10 nmol ICI-182780 on the clipped ventral surface (Fig. 5) . Hair growth was monitored on both the dorsal and ventral clipped surfaces of the treated mice, with the intention that if the effects were of a systemic nature, modulation of hair growth would be seen irrespective of the site of application. Application of 10 nmol of ICI-182780 promoted hair growth on the ventral surface (site of application) (Fig. 5A ) but had no effect on the hair growth on the dorsal surface (Fig. 5B ). E 2 (1 nmol) inhibited hair growth on the ventral surface (Fig. 5A) but not on the dorsal surface (Fig. 5B ). E 2 (10 nmol) inhibited hair growth on both the dorsal and the ventral surfaces, but the inhibition of hair growth on the dorsal surface (site away from the site of application) was much attenuated compared with the ventral surface (site of application). Similar results were found Total RNA was analyzed for ER transcripts, as described in MATERIALS AND METHODS. RNA skin sample designated A2 was derived from mouse skin (10 wk old) containing predominantly anagen hair follicles, whereas RNA skin samples designated T2 and T4 were derived from individual mouse skins (7 wk old) containing predominantly telogen hair follicles. Levels of cyclophilin (CYC) transcripts were used to compare loading levels between samples.
in experiments in which E 2 and ICI-182780 were applied on the clipped dorsal surface and hair growth was monitored on the clipped ventral surface (data not shown). Collectively, these results indicate that the hair growth-modulating effects of topically applied E 2 and ICI-182780 are occurring locally rather than systemically.
Effect of ovariectomy on hair growth. It is evident that the topical application of exogenous E 2 arrests hair follicles in telogen. Therefore, we wanted to determine whether removal of the ovaries, the major source of endogenous estrogen, would alter the hair follicle cycle. To this end, 6-wk-old female mice whose follicles were in the telogen phase of the hair follicle cycle were subjected to ovariectomy, and hair growth was monitored in this group and compared with the shamovariectomized group. As shown in Fig. 6 , ovariectomy caused a profound and rapid telogen-to-anagen transition, with accompanying full hair growth. To determine whether the effect of ovariectomy on hair growth could be prevented by topical application of E 2 , ovariectomized mice were treated twice weekly with 1 nmol E 2 . As shown in Fig. 6 , topical application of E 2 prevented the hair growth in ovariectomized mice. Although this dose of E 2 was without a systemic effect on hair growth in the dorsal-ventral experiment, we wanted to assure that cutaneous absorption of E 2 did not result in high sustained serum E 2 levels in ovariectomized mice. RIA analysis revealed that after topical application of 1 nmol E 2 , serum estradiol increased rapidly within 2 h to levels comparable with those found during proestrous in CD-1 mice (40) but declined to a low physiological range by 12 h (Fig. 7) . This rapid decline resulted in an abbreviated exposure to E 2 compared with the normal cycling mouse (40) . The uterus was capable of responding to these levels of estradiol with less than a half-maximal increase in wet weight (data not shown), whereas under similar topical dosing, hair growth was unaffected in the dorsal-ventral experiment. Therefore, these data further support the notion that the effect of E 2 on the hair follicle cycle is due to its direct action in the skin.
DISCUSSION
Estrogen receptors, as detected by Scatchard analysis, have been found in human (14, 31) and mouse skin (38) and, on the basis of [ 3 H]estrogen binding, are present in rat skin (36) . Utilizing a monoclonal antibody (H222) to ER, we have previously found that an ER immunoreactive protein was extensively expressed in the nuclei of the dermal papilla of the telogen follicles in mice (29) . These results provided direct evidence that the ER is expressed and that its expres- 6 . Effect of ovariectomy on hair regrowth in mice. Six-week-old mice with identical dates of birth were clipped on their dorsal surface and then subjected to ovariectomy (8 mice/group). Beginning from day of ovariectomy, mice were treated twice weekly on clipped dorsal surfaces with 1 nmol E 2 ( * ) in 200 µl acetone or acetone alone (s). Fig. 7 . Serum E 2 levels after topical application of E 2 . Six-week-old mice with identical dates of birth were clipped on dorsal surface and then subjected to ovariectomy. Beginning from day of ovariectomy, mice were treated twice weekly on clipped dorsal surfaces with 1 nmol E 2 in 200 µl acetone for 5 wk. Mice (4 mice/group) were then killed at 0, 2, 6, 12, 24, and 48 h after the last dosing to collect blood for determination of E 2 .
sion is localized to specific cells thought to be important in regulating the hair follicle cycle. However, two ERs have now been identified, and both ER-␣ and ER-␤ are expressed in numerous tissues (8, 32) . Therefore, it was necessary to determine whether ER-␣ and/or ER-␤ is expressed in mouse skin. We found that monoclonal antibodies H226 and H222, directed toward either the NH 2 -terminal transactivation A/B domain or to the carboxy-terminal F domain of ER-␣, respectively, recognize a 65-kDa protein in skin protein extracts. This 65-kDa size corresponds to the known size of the mouse ER-␣ protein (12, 16) . In addition, Northern blot analysis of RNA isolated from mouse skin probed with a mouse ER-␣ cDNA revealed a 6.7-kb mRNA that corresponds to the size of the mouse ER-␣ mRNA (41) . RPA analysis confirmed that ER-␣ transcripts are present in mouse skin and also demonstrated that ER-␤ transcripts are not detectable in mouse skin. These findings, coupled with the previous immunohistochemical localization studies, in which monoclonal antibody H222 detected an ER immunoreactive protein predominantly if not exclusively in the nuclei of the dermal papilla cells, indicate that it is ER-␣ that is expressed in the nuclei of dermal papilla cells of mouse skin.
Earlier studies from our laboratory demonstrated that the topical application of estrogen to mouse skin blocks hair growth by arresting the hair follicle in telogen and that the topical application of the ER antagonist ICI-182780 initiates hair growth by causing the telogen follicle to enter anagen. Although these data are supportive of a skin ER pathway, it is also possible that the effects of topically applied E 2 and ICI-182780 were due to a secondary systemic effect subsequent to dermal absorption. Our current results demonstrate that the ventral topical twice weekly application of either 10 nmol ICI-182780 or 1 nmol E 2 produces hair growth effects at the site of application but not at remote sites away from the site of application. These results indicate that the effects of E 2 and ICI-182780 on hair growth are mediated locally within the skin and are not due to a secondary systemic effect. Furthermore, the fact that topically applied ICI-182780 can prevent the hair growth-inhibitory action of topically applied E 2 provides additional evidence for a skin ER-␣ pathway that regulates the telogen-anagen hair follicle transition in mice.
We found that topical application of 1 nmol E 2 to mouse skin resulted in a rapid increase in serum E 2 levels that returned to low physiological levels within 12 h, indicating that E 2 is rapidly absorbed through mouse skin and rapidly cleared from the serum. Whereas the serum levels of E 2 are not sustained after topical application, a single E 2 dose every 3-4 days is sufficient to maintain the hair follicle in telogen. Therefore, it appears that each E 2 treatment has a prolonged local inhibitory effect on the hair follicle cycle. Perhaps E 2 , through ER-␣, is inducing the expression of stable proteins that are sufficiently long-lived to block the telogen-anagen transition, or perhaps E 2 is sequestered in the skin. We found that topical E 2 treatment increases the amount of ER-␣ protein expression in skin,
suggesting that E 2 itself may be involved in the regulation of ER-␣ expression in skin. It is possible that this increase in ER-␣ protein is sufficient to induce or maintain the putative telogen regulatory signal. In support of this notion are results demonstrating that the levels of ER-␣ in skin are decreased in ICI-182780-treated mice as well as in the skin of control mice whose follicles have cycled into anagen. In addition, previous studies have demonstrated the absence of the ER immunoreactive protein in the dermal papilla of anagen follicles (29) .
The fact that E 2 and estrone are produced by the hair follicle itself (35) and that within the skin the ER is predominantly expressed in the dermal papilla (29) suggests that estrogen may function as a paracrine regulator of the hair follicle cycle. However, we found that ovariectomy does induce a rapid telogen-anagen transition with accompanying hair growth and that this effect can be blocked by twice weekly topical application of 1 nmol E 2 , a dose that has hair growth effects only at the site of treatment. These results suggest that the skin is dependent on serum estrogen or ovarian precursor steroids for the regulation of the telogen-anagen transition. However, it does not appear that the estrous cycle alters or controls the hair follicle cycle in mice. For example, 6-wk-old female mice are reproductively mature and actively cycling, yet the hair follicles of these mice are arrested in telogen from the age of 6 wk to 9 wk. Thus, over this 3-wk period, these mice have undergone ϳ5 estrous cycles, indicating that the hair follicle cycle is independent of the high and low levels of serum E 2 that occur during proestrus and diestrus, respectively. Although it is possible that the effects of ovariectomy are due to events other than or in addition to the decrease in serum estrogen, it is clear that topical treatment with estrogen can prevent the effects of ovariectomy on hair growth. Because ER-␣ can be activated via an epidermal growth factor receptor pathway in a ligand-independent manner in reproductive tissues (18) , additional pathways could be operative in the hair follicle as well. Collectively, our results suggest that estrogen production and uptake in skin are complex and that further investigation will be required to clarify the pathways that regulate the presence of dermal estrogens and link them with inhibition of hair growth.
Although androgens have been extensively studied as regulators of hair follicle growth and differentiation (34) , estrogens have received comparatively little attention. Recently, inhibitors of 5␣-reductase have hair growth-promoting properties, indicating an inhibitory role for DHT on hair growth (10, 21) . Our current results in mice demonstrate that among the steroids examined, which included E 2 , testosterone, DHT, progesterone, and androstenedione, E 2 is the most effective at blocking hair growth. Based on the hair growthinhibitory action of 1 nmol E 2 , it appears that E 2 is Ն10-fold more potent than DHT. ER-binding proteins have been identified in human skin (14, 31) and may represent potential targets for hair growth modulation by E 2 or ICI-182780. Among the ER antagonists exam-ined, ICI-182780 is the most potent at inducing hair growth. All of the ER antagonists examined promoted the telogen-anagen transition and hair growth to some extent; however, higher doses actually inhibited hair growth. The decreased activity of these ER antagonists, as well as their inhibitory action at higher doses, is consistent with the fact that these compounds are partial agonists of ER (20) .
In summary, the growth and cyclicity of a hair follicle are controlled through complex and intricate interactions between the epithelial cells of the follicle and mesenchymal cells of the dermal papilla. Although it has been suggested that diffusible factors derived from the dermal papilla cells regulate the follicle cycle, the exact nature of these factors is still unknown. The identification of regulatory molecules such as estrogen and ER antagonists that modulate the telogen-toanagen transition could allow for the identification of the downstream effectors of ER-␣. Identification of the effector pathways may allow for the development of effective therapy to treat hair-related abnormalities like alopecia and hirsutism.
